Efficacy and safety of rituximab second-line therapy for membranous nephropathy: A prospective, matched-cohort study

American Journal of Nephrology

Volumn 33, Issue 5, 2011, Pages 461-468

  Cravedi, Paolo ^a   Sghirlanzoni, Maria Chiara ^b   Marasà, Maddalena ^b   Salerno, Alessandra ^b   Remuzzi, Giuseppe ^a,b   Ruggenenti, Piero ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Membranous nephropathy; Nephrotic syndrome; Remission; Rituximab

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN G; RITUXIMAB; STEROID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DISEASE; LEUKOPENIA; MALE; MEMBRANOUS GLOMERULONEPHRITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RELAPSE; REMISSION; TREATMENT OUTCOME;

ADULT; ALKYLATING AGENTS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOPSY; COHORT STUDIES; CYCLOSPORINE; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; REMISSION INDUCTION;

EID: 79954619552     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000327611     Document Type: Article

References (32)

1. Swaminathan S, Leung N, Lager DJ, Melton LJ 3rd, Bergstralh EJ, Rohlinger A, Fervenza FC: Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. Clin J Am Soc Nephrol 2006;1:483-487.
2. Ronco P, Debiec H: Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. J Am Soc Nephrol 2010;21:564-569.
3. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: M-type phospholipase A 2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361:11-21.
4. Ronco P, Debiec H, Guigonis V: Mechanisms of disease: alloimmunization in renal diseases. Nat Clin Pract Nephrol 2006;2:388-397. (Pubitemid 44034189)
5. Cohen CD, Calvaresi N, Armelloni S, Schmid H, Henger A, Ott U, Rastaldi MP, Kretzler M: CD20-positive infiltrates in human membranous glomerulonephritis. J Nephrol 2005;18:328-333. (Pubitemid 41078956)
6. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P: Rituximab for idiopathic membranous nephropathy. Lancet 2002;360:923-924. (Pubitemid 35283838)
7. Ruggenenti P, Cravedi P, Sghirlanzoni MC, Gagliardini E, Conti S, Gaspari F, Marchetti G, Abbate M, Remuzzi G: Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin J Am Soc Nephrol 2008;3:1652-1659.
8. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G: Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003;14:1851-1857. (Pubitemid 36750480)
9. Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH: Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol 2009;4:734-744.
10. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, Leung N, Cohen IM, Wochos DN, Bergstralh E, Hladunewich M, Cattran DC: Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008;73:117-125. (Pubitemid 350273646)
11. Segarra A, Praga M, Ramos N, Polanco N, Cargol I, Gutierrez-Solis E, Gomez MR, Montoro B, Camps J: Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol 2009;4:1083-1088.
12. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC: Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 2004;66:1199-1205. (Pubitemid 39121029)
13. Goumenos DS, Katopodis KP, Passadakis P, Vardaki E, Liakopoulos V, Dafnis E, Stefanidis I, Vargemezis V, Vlachojannis JG, Siamopoulos KC: Corticosteroids and cyclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs. Am J Nephrol 2007;27:226-231. (Pubitemid 47164670)
14. Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY: Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010;89:255-262.
15. Gay J: Clinical epidemiology and evidencebased medicine glossary: clinical study design and methods terminology. Available at http://www.vetmed. wsu.edu/courses-jmgay/GlossClinStudy.htm (accessed August 3, 2010).
16. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G: Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007;2:932-937.
17. Ruggenenti P, Perticucci E, Cravedi P, Gambara V, Costantini M, Sharma SK, Perna A, Remuzzi G: Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 2008;19:1213-1224.
18. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL: Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized tria l. K idney Int 2001;59:1484-1490. (Pubitemid 32281239)
19. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, Melis P, Valzorio B, Sasdelli M, Pasquali S, Pozzi C, Piccoli G, Lupo A, Segagni S, Antonucci F, Dugo M, Minari M, Scalia A, Pedrini L, Pisano G, Grassi C, Farina M, Bellazzi R: A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998;9:444-450. (Pubitemid 28122870)
20. Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G: Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis 2004;44:385-401. (Pubitemid 39164615)
21. Fedor ME, Rubinstein A: Effects of longterm low-dose corticosteroid therapy on humoral immunity. Ann Allergy Asthma Immunol 2006;97:113-116. (Pubitemid 44156348)
22. Turk JL, Parker D: Effect of cyclophosphamide on immunological control mechanisms. Immunol Rev 1982;65:99-113. (Pubitemid 12068795)
23. Kessel A, Rosner I, Toubi E: Rituximab: beyond simple B cell depletion. Clin Rev Allergy Immunol 2008;34:74-79.
24. Winter MC, Hancock BW: Ten years of rituximab in NHL. Expert Opin Drug Saf 2009;8:223-235.
25. Salliot C, Dougados M, Gossec L: Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009;68:25-32.
26. Gurcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR: A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009;9:10-25.
27. Lindholm C, Borjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M: Long-term clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J R heumatol 2008;35:826-833. (Pubitemid 351747123)
28. Marasa M, Kopp JB: Monoclonal antibodies for podocytopathies: rationale and clinical responses. Nat Rev Nephrol 2009;5:337-348.
29. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL: Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834-4840.
30. Kavanaugh A, Matteson E: Rituximab and progressive multifocal leukoencephalopathy. American College of Rheumatology. http://www.rheumatology. org/publications/hotline/0107leuko.asp.
31. Nived O, Bengtsson AA, Jonsen A, Sturfelt G: Progressive multifocal leukoencephalopathy - the importance of early diagnosis illustrated in four cases. Lupus 2008;17:1036-1041.
32. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X, Cattran DC: Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 2011;5:2188-2198.